Aminosalicylates for induction of remission or response in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  Lim, Wee Chian ^a   Wang, Yongjun ^b   Macdonald, John K ^c,d   Hanauer, Stephen ^e  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b WESTERN UNIVERSITY   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; CORTICOSTEROID; MESALAZINE; SALAZOSULFAPYRIDINE; BUDESONIDE; DELAYED RELEASE FORMULATION; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE;

CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; DELAYED RELEASE FORMULATION; INDUCTION CHEMOTHERAPY; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUDESONIDE; CROHN DISEASE; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL AGENTS; HUMANS; INDUCTION CHEMOTHERAPY; MESALAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFASALAZINE;

EID: 84977656695     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008870.pub2     Document Type: Review

References (135)

1. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clinical Gastroenterology and Hepatology 2004;2(5):379-88.
2. Hoechst Marion Roussel Inc. Clinical study report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's III). January 28, 1997.
3. Gross V, Andus T, Fischbach W, Weber A, Gierend M, Hartmann F, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Zeitschrift fur Gastroenterologie 1995;33(10):581-4.
4. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45(2):88-92.
5. Maier K, Fruhmorgen P, Bode JC, Heller T, von Gaisberg U, Klotz U. Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid. Deutsche Medizinische Wochenschrift 1985;110(10):363-8.
6. Maier K, Frick HJ, Von Gaisberg U, Teufel TH, Klotz U. Clinical efficacy of oral mesalamine in Crohn's disease. Can J Gastroenterol 1990;4(1):13-8.
7. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86(2):249-66.
8. Martin F, Sutherland L, Beck IT, Anderson AH, Williams CN, Saibil F, et al. Oral 5-ASA versus prednisolone in short term treatment of Crohn's disease: A multicentre controlled trial. Canadian Journal of Gastroenterology 1990;4(7):452-7.
9. Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116(3):521-6.
10. Rasmussen SN, Lauritsen K, Tage-Jensen U, Nielsen OH, Bytzer P, Jacobsen O, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scandinavian Journal of Gastroenterology 1987;22(7):877-83.
11. Rijk MC, van Hogezand RA, van Lier HJ, van Tongeren JH. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. Annals of Internal Medicine 1991;114(6):445-50.
12. Saverymuttu SH, Gupta S, Keshavarzian A, Donovan B, Hodgson HJ. Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease. Digestion 1986;33(2):89-91.
13. Jenss H, Hartmann F, Schölmerich J, und Deutsche 5-ASA Studiengruppe. 5-Aminosalicylic acid versus methylprednisolone in the therapy of acute Crohn's disease - results of a double-blind multicentric clinical study [5-aminosalicylsäure versus methylprednisolon in der therapie des aktiven morbus Crohn - ergebnisse einer doppelblinden multizentrischen klinischen studie]. Klinische Wochenschrift 1990;68(Suppl 19):34.
14. Scholmerich J, Jenss H, Hartmann F, Dopfer H. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Canadian Journal of Gastroenterology 1990;4(7):446-51.
15. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Digestive Diseases and Sciences 1995;40(5):931-5.
16. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104(5):1293-301.
17. Nordic Research Inc. Clinical research report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's II). October 23, 1991.
18. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107(2):632-3.
19. Singleton JW. Results of treatment with sulfasalazine in the American Multicenter Study on the treatment of Crohn disease (National Cooperative Crohn's Disease Study) [Ergebnisse der behandlung mit sulfasalazine der amerikanischen multcienter-studie zur behandlung des morbus Crohn (National Cooperative Crohn's Disease Study [NCCDS])]. Zeitschrift fur Gastroenterologie - Verhandlungsband 1981 Jun;19:38-40.
20. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77(4 Pt 2):870-82.
21. Summers RW, Singleton JW. National Cooperative Crohn's Disease Study (NCCDS): a controlled prospective trial of three drugs vs placebo. Gut 1977;18(11):A972-3.
22. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69.
23. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. New England Journal of Medicine 1998;339(6):370-4.
24. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. American Journal of Gastroenterology 2002 Mar;97(3):649-53.
25. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. Journal of Clinical Gastroenterology 1994;19(4):278-82.
26. Tromm A, Bungani I, Tomsová E, Tulassay Z, Luká M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm H, J.Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011;140(2):425-34.
27. Tromm A, Bunganic I, Tomsová E, Tulassay Z, Lukas M, Kykal J, et al. Both budesonide (9mg) as well as high-dose eudragit-l-coated mesalamine(4.5g) lead to high remission rates in moderately active Crohn's disease patients: a double-blind, double-dummy, randomized, multicenter study. Gastroenterology 2009;136(5 supplement 1):A65.
28. Van Hees PA, Van Lier HJ, Van Elteren PH, Driessen M, Van Hogezand RA, Ten Velde GP, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981;22(5):404-9.
29. van Hees P, ten Velde G, van Hogezand R, Driessen W, Bakker J, Van Lier H, et al. Effect of sulphasalazine in patients with Crohn's disease. a controlled double-blind trial. Hepato-Gastroenterology 1980;27(SUPPL.):E38.5.
30. van HeesP, van Hogezand R, Ten Velde G. Effect of sulphasalazine in patients with active Crohn's disease. a controlled double-blind trial. Netherlands Journal of Medicine 1981;24(4):157.
31. Wright JP, Jewell DP, Modigliani R, Malchow H. A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflammatory Bowel Diseases 1995;1(4):241-6.
32. Salazopyrin in the management of Crohn's disease. The Japanese Research Committee for Crohn's disease. Gastroenterologia Japonica 1985;20(1):71-81.
33. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group. Alimentary Pharmacology and Therapeutics 1990;4(1):55-64.
34. Anthonisen P, Barany F, Folkenborg O, Holtz A, Jarnum S, Kristensen M, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scandinavian Journal of Gastroenterology 1974;9(6):549-54.
35. Anthonisen P, Bárány F, FolkenborgO, Holtz A, Jarnum S, KristensenM, et al. The clinical effect of salazosulphapyridine (Salazopyrin) in Crohn's disease. Report of a controlled double blind investigation. Ugeskrift for Laeger 1974;136(32):1798-802.
36. Arber N, Odes HS, Fireman Z, Lavie A, Broide E, Bujanover Y, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. Journal of Clinical Gastroenterology 1995;20(3):203-6.
37. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127(3):730-40.
38. Beck IT, Hudacin J, Paterson WG, Depew WT, Simon JB, Groll A. Mesalazine in the treatment of active Crohn's disease. Canadian Journal of Gastroenterology 1988;2(Suppl A):63A-70A.
39. Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scandinavian Journal of Gastroenterology 1976;11(7):651-6.
40. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scandinavian Journal of Gastroenterology 1978;13(1):123-7.
41. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience. International Journal of Clinical Pharmacology Research 1994;14(4):133-8.
42. Brignola C, Iannone P, Pasquali S, Campieri M, Gionchetti P, Belluzzi A, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Digestive Diseases and Sciences 1992;37(1):29-32.
43. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995;108(2):345-9.
44. Caprilli R, Andreoli A, Capurso L, Corrao G, D'Albasio G, Gioieni A, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology and Therapeutics 1994;8(1):35-43.
45. Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Alimentary Pharmacology and Therapeutics 2003;17(4):517-23.
46. Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterologie Clinique et Biologique 2009;33(1 pt 1):31-40.
47. Cohen Z. Crohn's disease - Outcome of surgery. Drugs of Today 2000;36(Suppl G):51-7.
48. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). American Journal of Gastroenterology 1999;94(3):674-8.
49. de Franchis R, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Alimentary Pharmacology and Therapeutics 1997;11(5):845-52.
50. Del Corso L, Moruzzo D, Romanelli AM, Norpoth M, Pentimone F, Bresci G. [5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease]. Deutsche Medizinische Wochenschrif 1995;120(50):1723-7.
51. Dirks E, Goebell H, Schaarschmidt K, Forster S, Quebe-Fehling E, Eigler FW. Clinical relapse of Crohn's disease under standardized conservative treatment and after excisional surgery. Digestive Diseases and Sciences 1989;34(12):1832-40.
52. Ewe K, Holtermuller KH, Baas U, Eckhart V, Krieg H, Kutzner J, et al. [Prevention of recurrence by salazosulfapyridine (azulfidine) therapy in Crohn's disease. A double blind study]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin 1976;82 Pt 1:930-2.
53. Ewe K, Malchow H, Herfarth, C . Radical operation and recurrence prevention with azulfidine in Crohn disease: a prospective multicenter study--initial results [Operative Radikalitat und Rezidivprophylaxe mit Azulfidine bei M. Crohn: Eine prospektive multizentrische Studie--Erste Ergebnisse.]. Langenbecks Archiv für Chirurgie 1984;364:427-30.
54. Ewe K, Herfarth Ch, Malchow H, Jesdinsky H. Crohn study II: Influence of surgical radicality and salazosulfapyridine prophylaxis on postoperative relapses. Klinische Wochenschrift 1986;64:50-1.
55. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989;42(4):224-32.
56. Fiasse R, Fontaine F, Van Heuverzwijn R, Biemans M. Prevention of Crohn's disease recurrences after intestinal resection with eudragid-l-coated 5-aminosalicylic acid. An interim report of a one year double-blind placebo controlled study (ABSTRACT). Acta Gastroenterologica Belgica 1990;53(1):A11.
57. Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). European Journal of Gastroenterology and Hepatology 1996;8(3):229-33.
58. Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soule JC, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104(2):435-9.
59. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. [Therapy of active Crohn disease with Boswellia serrata extract H 15]. Zeitschrift fur Gastroenterologie 2001;39(1):11-7.
60. Goldstein F, Farquhar S, Thornton JJ, Abramson J. Favorable effects of sulfasalazine on small bowel Crohn's disease: a long-term study.". American Journal of Gastroenterology 1987;82(9):848-853.
61. Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition 1993;17(2):186-92.
62. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive Diseases and Sciences 2000;45(7):1462-4.
63. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. American Journal of Gastroenterology 1993;88(9):1343-51.
64. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127(3):723-9.
65. Howaldt S, Raedler A, Reinecker HC, Berghaus D, Hoyer S, Kaiser B, et al. Comparative trial of remission prophylaxis in quiescent Crohn's disease with oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Can J Gastroenterol 1993;7(2):241-4.
66. Klein O, Colombel JF, Lescut D, Gambiez L, Desreumaux P, Quandalle P, et al. Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease. Am J Gastroenterol 1995;90(11):1949-52.
67. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. New England Journal of Medicine 1980;303(26):1499-502.
68. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. Gut 1977;18(1):69-72.
69. Lichtenstein GR, Ramsey D. Experience with delayed-release mesalamine for maintenance of remission of Crohn's disease (CD). Gastroenterology 2009;136(5):A661-2.
70. Lichtenstein GR, Ramsey D. Experience with delayed-release mesalamine for active Crohn's disease (CD). Gastroenterology 2009;136(5):A657-8.
71. Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M, Vogelsang H, Sommer H, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology 1991;101(4):881-8.
72. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118(2):264-73.
73. Mahmud N, Kamm MA, Dupas JL, Jewell DP, O'Morain CA, Weir DG, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001;49(4):552-6.
74. Malchow H, Steinhardt HJ, Lorenz-Meyer H, Strohm WD, Rasmussen S, Sommer H, et al. Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. Scandinavian Journal of Gastroenterology 1990;25(3):235-44.
75. Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Clinical Gastroenterology and Hepatology 2003;1(2):122-8.
76. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology 2000;12(11):1227-33.
77. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O'Rourke K, Andrews DF, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995;109(2):404-13.
78. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110(3):688-93.
79. Orlando A, Mocciaro F, Scimeca D, Rispo A, Scribano ML, Testa A, et al. Early post-operative endoscopic recurrence in crohn's disease in a large prospective Italian multicenter cohort. Digestive and Liver Disease 2012;44:S81.
80. Papi C, Aratari A, Tornatore V, Koch M, Capurso L, Caprilli, R . Long-term prevention of post-operative recurrence in Crohn's disease cannot be affected by mesalazine. Journal of Crohn's and Colitis 2009;3(2):109-14.
81. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992;103(2):363-8.
82. Rasmussen SN, Binder V, Maier K, Bondesen S, Fischer C, Klotz U, et al. Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 1983;85(6):1350-3.
83. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59(6):752-9.
84. Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World Journal of Gastroenterology 2005;11(45):7118-21.
85. Rosen A, Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. Gastroenterology 1982;83(3):541-9.
86. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83(3):550-62.
87. Savarino E, Bodini G, Dulbecco P, Marabotto E, Assandri L, Bruzzone L, Mazza F, Fazio V, Giambruno E, Gemignani L, Savarino V. Adalimumab Is More Effective Than Azathioprine and Mesalamine At Preventing Postoperative Recurrence of Crohn's Disease - A Randomized Trial. Gastroenterology 2013;144(5):S21.
88. Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF. [Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study]. Deutsche Medizinische Wochenschrift 1985;110(45):1724-30.
89. Schreiber S, Howaldt S, Raedler A. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Gut 1994;35(8):1081-5.
90. Singleton JW, Summers RW, Kern F Jr, Becktel JM, Best WR, Hansen RN, et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979;77(4 Pt2):887-97.
91. Stober B, Nutzenadel W, Ullrich F. [Basic diet in Crohn's disease]. Monatsschr Kinderheilkd 1983;131(10):721-4.
92. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997;112(4):1069-77.
93. Tao, Q. S.Ren, J. A.Ji, Z. L.Li, J. S.Wang, X. B.Jiang, X. H. Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease. Zhonghua Wei Chang Wai Ke Za Zhi 2009;12(5):491-3.
94. Terranova M, Leonello G, Macri A, Versaci A, Scuderi G, Crisafulli C, et al. Enteral nutrition in the short-term treatment of active inflammatory bowel diseases: A single-centre experience. Rivista Italiana di Nutrizione Parenterale ed Enterale 2001;19(1):12-7.
95. Terrin G, Canani RB, Ambrosini A, Viola F, De Mesquita MB, Di Nardo G, Dito L, Cucchiara S. A semielemental diet (Pregomin) as primary therapy for inducing remission in children with active Crohn's disease. Italian Journal of Pediatrics 2002;25(5):401-5.
96. Thomson AB, Wright JP, Vatn M, Bailey RJ, Rachmilewitz D, Adler M, et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Alimentary Pharmacology and Therapeutics 1995;9(6):673-83.
97. Triantafillidis JK, Stamataki A, Karagianni V, Gikas A, Malgarinos G. Maintenance treatment of Crohn's disease with a polymeric feed rich in TGF-beta. Annals of Gastroenterology 2010;23(2):113-8.
98. Wellmann W, Fink PC, Benner F, Schmidt FW. Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut 1986;27(7):814-20.
99. Wellmann W, Schroder U. New oral preparations for maintenance therapy in Crohn's disease (abstract). Canadian Journal of Gastroenterology 1988;2(Supplement A):71A-2.
100. Wenckert A, Kristensen M, Eklund AE, Barany F, Jarnum S, Worning H, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial. Scand J Gastroenterol 1978;13(2):161-7.
101. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflammatory Bowel Diseases 2009;15(10):1460-6.
102. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2(8044):892-5.
103. Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115(4):835-40.
104. Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978. Gastroenterology 1982;83(3):563-8.
105. Brant R, Sutherland L, Hilsden R. Examining the minimum important difference. Statistics in Medicine 1999;18(19):2593-603.
106. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41(2):209-14.
107. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994;35(2):231-5.
108. De Dombal FT, Burton IL, Clamp SE, Goligher JC. Short-term course and prognosis of Crohn's disease. Gut 1974;15(6):435-43.
109. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
110. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006;55(9):1341-9.
111. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clinical Gastroenterology and Hepatology 2004;2(5):376-8.
112. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. European Journal of Gastroenterology and Hepatology 1996;8(9):905-9.
113. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
114. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. American Journal of Gastroenterology 2001;96(3):635-43.
115. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Reviews in Gastroenterological Disorders 2003;3(2):81-92.
116. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clinical Gastroenterology and Hepatology 2004;2(5):379-88.
117. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors(s) editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
118. Levesque BG, Sandborn WJ. Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. Inflammatory Bowel Diseases 2012;18(4):795-6.
119. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology 2004;126(6):1504-17.
120. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. American Journal of Gastroenterology 2000;95(12):3343-5.
121. Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Research 2004;129(1):39-44.
122. Rao SS, Read NW, Holdsworth CD. Influence of olsalazine on gastrointestinal transit in ulcerative colitis. Gut 1987;28(11):1474-7.
123. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. Journal of Experimental Medicine 2005;201(8):1205-15.
124. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. New England Journal of Medicine 1994;331(13):842-5.
125. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. American Journal of Gastroenterology 2002;97(12):2939-41.
126. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122(2):512-30.
127. Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm. Alimentary Pharmacology and Therapeutics 2003;18(3):263-77.
128. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004;53(10):1485-93.
129. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807-18.
130. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editors(s) editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
131. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126(5):1257-69.
132. Thomsen OO. A comparison of budesonide and mesalamine for active Crohn's disease. Correction. New England Journal of Medicine 2001;345(22):1652.
133. Tvede M, Bondesen S, Nielsen OH, Rasmussen SN. Serum antibodies to Bacteroides species in chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1983;18(6):783-9.
134. Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 1991;41(4):647-64.
135. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD008870]